Shanghai Pharmaceutical (601607.SH) plans to invest 300 million yuan to participate in the Shanghai Shangshi Biomedical Industry Private Equity Fund

Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) announced that the company plans to participate in the establishment of the Shanghai Shangshi Biomedical Industry Private Equity Fund Partnership (Limited Partnership) as one of the limited partners, with a proposed capital of 300 million yuan. The target fundraising scale of the fund is 2 billion yuan.

Participating in the establishment of the target fund is expected to better connect Shanghai Pharmaceutical's innovation system construction with the “Big BD” strategy, and build an internal closed-loop ecosystem of “early discovery+transformation of achievements+commercial implementation” through multi-dimensional collaboration such as pipelines, commerce, exit, team and mechanism. By prioritizing the delivery of cutting-edge innovation achievements and promoting high-quality assets to be accepted by Shanghai Pharmaceutical on a priority basis, the target fund can not only provide Shanghai Pharmaceutical with a high-quality early project pool, but also effectively control investment risks, and achieve accurate replenishment of R&D pipelines and systematic improvement of project transformation efficiency.